METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH)
Clinical trials for METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH) explained in plain language.
Never miss a new study
Get alerted when new METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH) trials appear
Sign up with your email to follow new studies for METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug tested to fight advanced liver scarring
Disease control CompletedThis study tested an experimental drug called BI 770371 in people with advanced liver scarring (cirrhosis) caused by MASH, a serious fatty liver disease. Twenty-eight participants were randomly assigned to receive either the drug or a placebo via IV infusion every three weeks for…
Matched conditions: METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH)
Phase: PHASE2 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Mar 27, 2026 12:39 UTC
-
Doctors and patients surveyed on understanding of silent liver disease
Knowledge-focused CompletedThis study was a survey to understand how much doctors, patients, and at-risk people know about a liver condition called MASH and its links to heart and kidney problems. Over 1,300 participants from five countries completed a 25-minute online questionnaire. The study did not test…
Matched conditions: METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH)
Sponsor: Novo Nordisk A/S • Aim: Knowledge-focused
Last updated Mar 27, 2026 12:40 UTC